Business5 hours ago
OS Therapies Unveils Q3 2025 Results and Upcoming Regulatory Steps
OS Therapies Inc. (NYSE American: OSTX), a leader in listeria-based cancer immunotherapies, announced its third quarter 2025 financial results and provided a comprehensive business update. The...